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The natural anticoagulant protein C (PC) pathway plays a major role in regulating 
coagulation and inflammation (reviews 1-3). PC is activated at the endothelial surface when 
thrombin binds to thrombomodulin (TM), a transmembrane glycoprotein, that transforms 
thrombin into a potent activator of PC. In the presence of its cofactor protein S, activated 
protein C (APC) inactivates factors Va and VIIIa, thereby downregulating the thrombin 
feedback loop. Thrombomodulin is a vascular endothelial cell receptor present in many cells 
and tissues. Its density is higher in small vessels and capillaries, however, and this is why PC 
activation was believed to occur mainly in these vessels. However, thrombosis in subjects 
with hereditary PC or PS deficiency is not restricted to the microcirculation but can also affect 
larger vessels, suggesting that the PC pathway is also active in zones of lower TM density. 
This apparent paradox was resolved by the discovery of an endothelial cell receptor specific 
for PC -- the endothelial cell protein C receptor (EPCR)-- which increases the PC activation 
rate by thrombin-TM complexes (4) and is most abundant in large vessels (5). Functional 
studies performed in vitro showed a 20-fold increase in the PC activation rate by membrane 
thrombin-thrombomodulin complexes when PC was bound to its receptor (6). This increase 
results from a significant effect of EPCR on the Michaelis-Menten constant (Km) for PC 
activation by the thrombin-thrombomodulin complex. Indeed, without EPCR intervention, 
this Km is significantly higher (1 µM) than the circulating concentration of PC (60-70 nM). 
By presenting PC to the thrombin-TM complex (Figure 1), EPCR reduces the Km and allows 
the interaction to occur. 
Compared to the effect of thrombin binding to TM, which results in a >1000-fold 
increase in the PC activation rate (7), the 20-fold increase in the PC activation rate after PC 
binding to EPCR might seem rather inconsequential. Yet, EPCR is even more important for 
PC activation than suggested by in vitro studies. Indeed, in a baboon model, APC generation 
induced by thrombin infusion fell by 88% when the animals were pretreated with anti-EPCR 
antibodies that blocked the PC/EPCR interaction (8). The crucial role of EPCR was further 
confirmed by studies of PROCR knock-out mice (9): complete invalidation of the gene led to 
intrauterine death by fibrin deposition in embryonic trophoblast giant cells, leading to 
thrombosis at the maternal-embryonic interface. 
EPCR is a 46-Kda type 1 transmembrane glycoprotein homologous to major 
histocompatibility complex (MHC) class I/CD1 family proteins (review in 10). This 221-
amino-acid (aa) protein comprises an extracellular domain, a 25-aa transmembrane domain, 
and a very short (3-aa) intracytoplasmic sequence. The PROCR gene is located on 
chromosome 20, spans 8 kilobases, and possesses 4 exons (11). The first exon encodes the 5' 
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untranslated region and the signal peptide, exons 2 and 3 encode most of the extracellular 
domain, and exon 4 encodes the remaining parts of the protein and the 3' untranslated region. 
Very recently, EPCR has been shown to serve as a cellular binding site for FVII/FVIIa 
(12), the affinity of the interaction being similar to that for PC/APC. FVIIa-EPCR complexes 
do not activate coagulation on unstimulated endothelial cells. FVIIa-EPCR binding reduces 
FVIIa coagulant activity (13) (Figure 1). The complex does not modulate TF-FVIIa activation 
of factor X on stimulated endothelial cells, but FVIIa binding to EPCR facilitates FVIIa 
endocytosis, thus clearing FVIIa from the vascular bed. 
In addition to its role in regulating coagulation, EPCR is crucial for the 
antiinflammatory, antiapoptotic and proangiogenic effects of APC. APC prevents 
inflammation by downregulating tissue-factor and NFB expression, and by reducing the 
expression of subunits of the transcription factor NFB and, thus, the expression of NF B-
controlled genes (14). Antiapoptotic protein synthesis is promoted, while the production of 
proapoptotic proteins is reduced. APC inhibits cytokine signaling and TNF induction of cell-
surface adhesion molecule expression. Most of these effects are due to PAR-1 cleavage by 
APC bound to EPCR (15). Inflammation contributes to propagating coagulation, and this 
effect is thus countered by the anti-inflammatory effect of APC. 
A soluble form of EPCR (sEPCR) present in normal human plasma lacks the 
transmembrane and cytoplasmic domains. Like the membrane-associated form, sEPCR binds 
PC and APC with similar affinity. However, its binding to APC inhibits the anticoagulant 
activity of APC by abrogating its ability to inactivate factor Va, and its binding to PC 
precludes PC activation by thrombin-TM complexes (16) (Figure 2). Soluble EPCR has 
mainly procoagulant properties. Regarding its effects on inflammation, sEPCR has been 
shown to bind to activated neutrophils (17). Since it competes with membrane-associated 
form for APC binding, this could decrease PAR-1 signaling by APC, and thus limit the APC 
anti-inflammatory properties.  
Several situations can interfere with the antithrombotic and antiinflammatory properties 
of EPCR and thereby promote thrombosis. EPCR dysfunction, decreased membrane EPCR 
expression, and increased plasma sEPCR levels can theoretically increase the thrombotic risk.  
It must be kept in mind that studies designed to evaluate the influence of EPCR on the 
thrombotic risk come up against from two main hurdles. First, EPCR being a membrane 
protein, its deficiency cannot be measured with a plasma-based assay (contrary to PC and PS 
deficiencies, for example), and we do not yet know whether sEPCR levels reflect membrane 
EPCR expression. Second, while circulating concentrations of PC/APC and sEPCR seem too 
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low to induce complete APC inhibition, local concentrations of sEPCR might be sufficiently 
high to impair APC functions.  
 
Circumstances leading to decreased membrane EPCR expression and/or increased sEPCR 
levels 
 As with other key proteins of the PC pathway, mutations were expected to diminish 
EPCR expression and thus to be found in subjects with unexplained thrombosis. The first 
reported abnormality was a 23-base-pair insertion in PROCR exon 3 (17), leading to the 
synthesis of a truncated protein that is not expressed on endothelial surfaces. Although 
initially identified in subjects with deep venous thrombosis and myocardial infarction, the 
precise impact of this mutation on thrombosis is difficult to assess because its allelic 
frequency is low. Point mutations were then described within the promoter region, but their 
involvement in gene regulation could not be clearly demonstrated. 
 Another possible mechanism leading to dysfunction of EPCR-mediated coagulation-
regulating mechanisms consists of mutations (or polymorphisms) leading to increased levels 
of sEPCR. Approximately 15% to 20% of the general population (19) have plasma sEPCR 
levels between 200 and 800 ng/mL, whereas the remainder have levels below 180 ng/mL. We 
and others have shown that 50-80% of plasma sEPCR variations are under genetic control 
(20-22), and that most subjects with elevated sEPCR levels carry the A3 haplotype -- one of 
the four most frequent PROCR haplotypes in Caucasians. One of the four haplotype-tagging 
single nucleotide polymorphisms (Ht-SNP) characterizing the A3 haplotype is a g.A6036G 
substitution leading to a p.Ser219 to Gly substitution in the transmembrane domain of the 
protein. It was recently shown that sEPCR levels are higher in A3 carriers because the Gly219 
receptor isoform is more sensitive than the Ser219 isoform to sheddases such as the 
metalloprotease ADAM17 (23). While sEPCR was thought to be generated exclusively by 
shedding, we very recently identified an alternative mRNA splicing (24) that is particularly 
efficient in A3-carrying subject’s cells and generates a truncated mRNA lacking the sequence 
encoding the transmembrane and intracytoplasmic domains. The resulting protein is not able 
to anchor to the membrane; it is thus secreted and can be detected in the plasma of A3-
carrying subjects. 
Three case-control studies, each involving 350 to 450 thrombophilic patients, 
examined the A3 haplotype as an independent risk factor for venous thrombosis but gave 
contradictory results (20-22). While our case-control study pointed to a role of the A3 
haplotype in venous thrombosis (20), the other two studies showed no such effect. One of 
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these studies, however, showed an increased risk (odds ratio) of thrombosis in subjects with 
increased sEPCR levels, together with a protective effect of the A1 haplotype on venous 
thrombosis (21). Whether or not the A3 haplotype itself is a risk factor for venous thrombosis 
remains to be determined in larger studies of thrombophilic subjects.   
 The A3 haplotype has been examined in two studies as an associated risk factor for 
venous thrombosis. In the first, the authors observed more severe clinical expression of PC 
deficiency in A3-carrying subjects than in non-carriers (25). In this issue of the Journal, 
Navarro et al (26) describes the influence of PROCR haplotypes on the risk of thrombosis in 
FII g.20210A carriers. Using c.4600G and c.4678C as A3- and A1-Ht-SNPs, respectively, 
they observed a higher frequency of the A3 haplotype in propositi than in asymptomatic 
relatives, as well as younger age at disease onset in A3-carrying propositi than in A3-non 
carriers, and a lower probability of being free of thrombosis at age 40 years. Very 
interestingly, they observed that symptomatic carriers of the A3 haplotype had higher sEPCR 
levels than asymptomatic carriers. In addition, they found that the odds ratio for thrombosis 
increased with the sEPCR quartile in A3 carriers. This finding -- that only higher sEPCR 
levels are associated with an increased thrombotic risk -- might explain the conflicting results 
of the three above-mentioned studies examining the A3 haplotype as an independent risk 
factor for thrombosis. The A1 haplotype was found to have a non significant tendency to 
protect from thrombosis, confirming previous results obtained by this research group. As 
underlined by Navarro et al, it is surprising that the effect of the A3 haplotype is seen in 
subjects with FII g.20210A and not in those with FV Leiden (26). This points to a difference 
in the mechanisms underlying the prothrombotic effects of these two mutations. 
 The possible involvement of EPCR Gly219 (A3 haplotype) in arterial thrombosis has 
been evaluated in a prospective cohort of more than 2000 patients (28). A significantly higher 
frequency of coronary heart disease was observed in A3 homozygotes, and the A3 haplotype 
was also associated with an increased risk of coronary heart disease in type-2 diabetic 
patients. 
 
Acquired EPCR abnormalities and increased sEPCR levels 
 Quantitative or qualitative modifications of EPCR have been implicated in human 
systemic lupus erythematosus (SLE), a potentially fatal autoimmune disease affecting 
multiple organ systems. Immune complexes are believed to induce microvasculature injury, 
associated with thrombotic manifestations, inflammation, and widespread activation of the 
vascular endothelium. A recent study strongly suggests that the vascular dysfunction 
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characterizing SLE may be related to abnormal distribution of both soluble and membrane-
associated EPCR (29). In addition to significantly increased plasma sEPCR levels reported in 
SLE patients by Kurosawa et al (30), increased soluble EPCR levels are observed in cytokine-
stimulated endothelial cells in vitro, leading to reduced expression of membrane-bound 
EPCR. A3-carrying subjects were also more frequent in the SLE group than in the control 
group (29). These increased sEPCR levels may simply reflect endothelial dysfunction, but 
they might also contribute to a procoagulant phenotype and thus to the thrombosis observed in 
SLE. Moreover, among patients with SLE, A3 haplotype carriers are more prone to 
thrombosis than non-carriers.  
 Disseminated intravascular coagulation with purpura fulminans due to microvascular 
thrombosis is a frequent complication of sepsis and is particularly severe during 
meningococcal sepsis (31). This disorder results from complex dysregulation of hemostatic 
mechanisms, with activation of procoagulant pathways and impairment of the fibrinolytic 
system and natural anticoagulant pathways, especially the protein C pathway. Reduced PC 
levels are found in most patients with sepsis. PC infusion does not always increase APC 
levels, showing that PC activation is dysregulated in this setting. Histological studies of skin-
biopsy specimens (31) revealed evidence of thrombosis, together with consistently diminished 
TM staining and EPCR staining decreased in 80% of cases. 
 Thrombosis is a frequent complication of cancer. The thrombophilic phenotype of 
cancer cells is due to both a cystein protease and to expression of procoagulant factors such as 
TF. EPCR is expressed on the outer membrane of various cancer cell lines (32,33). APC 
binding to cancer cell EPCR reduces TF expression while inducing antiapoptotic genes. This 
cell-protective effect is normally beneficial but, in subjects with cancer, APC binding to 
EPCR stimulates PAR-1, and PAR-1-associated cellular responses contribute to tumor 
progression (34), possibly via IL-8 production, which stimulates tumor cell proliferation and 
metastasis.  
 In this issue of the Journal, Molina and coworkers (35) report the production of a 
truncated EPCR mRNA by HUVECs, similar to the isoform we described. More interestingly, 
Molina and coworkers showed that the corresponding protein was produced and secreted by 
cultured lung cancer cells. The sEPCR generated by this truncated mRNA can bind PC and 
APC, and these cells are therefore able to produce a soluble receptor that might compete with 
membrane-associated EPCR for APC binding. This would tend to limit cell proliferation. In 
addition, this sEPCR is able to bind FVIIa and to abolish its factor X-activating activity, that 
counteracts the procoagulant effect of APC binding to sEPCR. The description of this 
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secreted EPCR isoform opens the way to assessing the thrombotic risk in cancer patients 
according to the type of malignancy. 
 
Circumstances leading to inhibition of APC–membrane interaction: the case of anti-EPCR 
antibodies 
 A recent study from Hurtado et al showed that approximately 20% of patients with the 
antiphospholipid syndrome (APS) had anti-EPCR antibodies exceeding the amount observed 
in control subjects (36). Women with APS and a history of thrombosis had the highest anti-
EPCR antibody titers, and women who had anti-EPCR IgM had had multiple miscarriages. 
IgM fractions isolated from these patients potently inhibited PC activation on endothelial 
cells. These autoantibodies that block PC activation might lead to skin necrosis (37) by 
reducing APC levels. Low APC levels are a risk factor for thrombosis, and this might explain 
the multiple episodes of venous thrombosis experienced by APS patients with PC-activation-
blocking antibodies. EPCR is also crucial for preventing placental thrombosis and thus for 
maintaining pregnancy. By undermining both anticoagulant and antiinflammatory 
mechanisms, these antibodies could precipitate fetal death. Indeed, anti-EPCR antibodies 
have been identified in 80% of women having experienced a first episode of fetal death, the 
odds ratio for this outcome depending on the isotype of anti-EPCR antibodies (38). 
 As EPCR is present on arterial walls, anti-EPCR antibodies could theoretically impair 
coagulation in these vessels and thus play a role in arterial thrombosis. Among 165 young 
women who survived a first acute myocardial infarction, Montes et al found that IgA anti-
EPCR titers exceeded the cut-off value determined in this study in 22% of cases, compared to 
only 10% in a control group, while the OR increased with the titer (39). This strongly 




 EPCR levels vary in a wide variety of pathophysiologic conditions, and the 
consequences depend partly on whether it is the membrane-associated or soluble form that is 
affected. While the role of membrane-associated EPCR is clearly antithrombotic and anti-
inflammatory in physiological circumstances, the function of the circulating protein (if any) is 
unclear. The thrombotic risk associated with the A3 haplotype is controversial, and further 
studies involving larger numbers of patients are necessary. Any deleterious effect of this 
haplotype could be related to the consistently elevated sEPCR levels seen in A3 carriers. 
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 Many circumstances can lead to increased plasma sEPCR levels, but it is not always 
easy to tell whether the increase is the cause or an effect of the associated disorder. Given the 
systemic concentrations of PC and sEPCR, it is unlikely that sEPCR could impair PC 
activation or activity and thus express its procoagulant properties observed in vitro. And yet 
evidence continues to accumulate that sEPCR has a noteworthy role in controlling 
coagulation and, thus, thrombosis. 
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Figure 1: Schematic drawing of the anticoagulant and anti-inflammatory properties 
of membrane associated EPCR 
 
 
Figure 2: cartoon of the known properties of soluble EPCR. Plasma soluble EPCR 
originates from the membrane form by shedding, or from synthesis of a soluble isoform 
issued from an alternative splicing. 
